|
Name |
Rubiginosin B
|
Molecular Formula | C21H22O8 | |
IUPAC Name* |
[(6R,7R)-6-hydroxy-3-[(E)-3-hydroxyprop-1-enyl]-7-methyl-8-oxo-5,6-dihydro-1H-isochromen-7-yl] 2,4-dihydroxy-6-methylbenzoate
|
|
SMILES |
CC1=CC(=CC(=C1C(=O)O[C@@]2([C@@H](CC3=C(C2=O)COC(=C3)/C=C/CO)O)C)O)O
|
|
InChI |
InChI=1S/C21H22O8/c1-11-6-13(23)9-16(24)18(11)20(27)29-21(2)17(25)8-12-7-14(4-3-5-22)28-10-15(12)19(21)26/h3-4,6-7,9,17,22-25H,5,8,10H2,1-2H3/b4-3+/t17-,21-/m1/s1
|
|
InChIKey |
ZRJGOGLZGFEQJT-RIEYKTBPSA-N
|
|
Synonyms |
Rubiginosin B; Rubinosin A; CHEMBL4080026; ZRJGOGLZGFEQJT-RIEYKTBPSA-; J3.616.327E; [(6R,7R)-6-hydroxy-3-[(E)-3-hydroxyprop-1-enyl]-7-methyl-8-oxo-5,6-dihydro-1H-isochromen-7-yl] 2,4-dihydroxy-6-methylbenzoate
|
|
CAS | NA | |
PubChem CID | 11269635 | |
ChEMBL ID | CHEMBL4080026 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 402.4 | ALogp: | 1.4 |
HBD: | 4 | HBA: | 8 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 134.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 29 | QED Weighted: | 0.562 |
Caco-2 Permeability: | -5.398 | MDCK Permeability: | 0.00001270 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.826 |
Human Intestinal Absorption (HIA): | 0.284 | 20% Bioavailability (F20%): | 0.956 |
30% Bioavailability (F30%): | 0.91 |
Blood-Brain-Barrier Penetration (BBB): | 0.078 | Plasma Protein Binding (PPB): | 83.73% |
Volume Distribution (VD): | 0.841 | Fu: | 14.67% |
CYP1A2-inhibitor: | 0.916 | CYP1A2-substrate: | 0.252 |
CYP2C19-inhibitor: | 0.108 | CYP2C19-substrate: | 0.065 |
CYP2C9-inhibitor: | 0.372 | CYP2C9-substrate: | 0.604 |
CYP2D6-inhibitor: | 0.562 | CYP2D6-substrate: | 0.138 |
CYP3A4-inhibitor: | 0.813 | CYP3A4-substrate: | 0.191 |
Clearance (CL): | 7.207 | Half-life (T1/2): | 0.884 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.746 |
Drug-inuced Liver Injury (DILI): | 0.962 | AMES Toxicity: | 0.37 |
Rat Oral Acute Toxicity: | 0.717 | Maximum Recommended Daily Dose: | 0.977 |
Skin Sensitization: | 0.939 | Carcinogencity: | 0.553 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.391 |
Respiratory Toxicity: | 0.348 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003304 | 0.818 | D07MGA | 0.273 | ||||
ENC002211 | 0.775 | D04AIT | 0.234 | ||||
ENC002726 | 0.649 | D0K8KX | 0.230 | ||||
ENC003837 | 0.633 | D08NQZ | 0.226 | ||||
ENC002132 | 0.627 | D0J2NK | 0.222 | ||||
ENC002725 | 0.596 | D02GAC | 0.221 | ||||
ENC003615 | 0.583 | D0AZ8C | 0.221 | ||||
ENC003448 | 0.477 | D08LTU | 0.221 | ||||
ENC002798 | 0.472 | D07VLY | 0.217 | ||||
ENC003640 | 0.455 | D0C9XJ | 0.217 |